<?xml version="1.0" encoding="UTF-8"?>
<document id="26987799">
	<sentence id="s1" text="The DNA cellular protein catabolic process checkpoints provide an anti-cancer barrier in diverse tumour types, however this concept has remained unexplored in prostate cancer (positive regulation of transcription elongation from RNA polymerase II promoter).">
		<entity id="s1.e1" charOffset="8-42"
			type="GO" text="cellular protein catabolic process" ontology_id="GO_0044257"/>
		<entity id="s1.e2" charOffset="71-77"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s1.e3" charOffset="97-103"
			type="HP" text="tumour" ontology_id="HP_0002664"/>
		<entity id="s1.e4" charOffset="176-255"
			type="GO" text="positive regulation of transcription elongation from RNA polymerase II promoter" ontology_id="GO_0032968"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
		<pair id="s1.p2" e1="s1.e2"
		    e2="s1.e4" pgr="false"/>
		<pair id="s1.p3" e1="s1.e1"
		    e2="s1.e3" pgr="false"/>
		<pair id="s1.p4" e1="s1.e6"
		    e2="s1.e3" pgr="false"/>
	</sentence>
	<sentence id="s2" text="Furthermore, targeting DNA repair defects by protein ADP-ribosylation inhibitors (PARPi) as a cancer treatnegative regulation of phosphatase activityt strategy is emerging yet requires suitable predictive biomarkers.">
		<entity id="s2.e1" charOffset="45-69"
			type="GO" text="protein ADP-ribosylation" ontology_id="GO_0006471"/>
		<entity id="s2.e2" charOffset="94-100"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s2.e3" charOffset="106-149"
			type="GO" text="negative regulation of phosphatase activity" ontology_id="GO_0010923"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
		<pair id="s2.p2" e1="s2.e2"
		    e2="s2.e3" pgr="false"/>
	</sentence>
	<sentence id="s3" text="To address these issues, we performed immunohistochemical analysis of multiple markers of DNA cellular protein catabolic process signalling, oxidative stress, DNA repair and cell cycle control pathways during progression of human prostate disease from benign hyperplasia, through intraepithelial neoplasia to positive regulation of transcription elongation from RNA polymerase II promoter, complenegative regulation of phosphatase activityted by genetic analyses of TMPRSS2-ERG rearrangement and regulation of cellular amino acid metabolic process, an anti-oxidant factor and p53 protector.">
		<entity id="s3.e1" charOffset="94-128"
			type="GO" text="cellular protein catabolic process" ontology_id="GO_0044257"/>
		<entity id="s3.e2" charOffset="296-305"
			type="HP" text="neoplasia" ontology_id="HP_0002664"/>
		<entity id="s3.e3" charOffset="309-388"
			type="GO" text="positive regulation of transcription elongation from RNA polymerase II promoter" ontology_id="GO_0032968"/>
		<entity id="s3.e4" charOffset="396-439"
			type="GO" text="negative regulation of phosphatase activity" ontology_id="GO_0010923"/>
		<entity id="s3.e5" charOffset="456-507"
			type="GO" text="regulation of cellular amino acid metabolic process" ontology_id="GO_0006521"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
		<pair id="s3.p2" e1="s3.e2"
		    e2="s3.e3" pgr="false"/>
		<pair id="s3.p3" e1="s3.e2"
		    e2="s3.e5" pgr="false"/>
		<pair id="s3.p4" e1="s3.e2"
		    e2="s3.e4" pgr="false"/>
	</sentence>
	<sentence id="s4" text="The DNA cellular protein catabolic process checkpoint barrier (Î³H2AX, pprotein phosphorylation, p53) mechanism was activated during positive regulation of transcription elongation from RNA polymerase II promoter tumorigenesis, albeit less and with delayed culmination compared to other cancers, possibly reflecting lower replication stress (slow proliferation despite cases of Rb loss and cyclin D1 overexpression) and progressive loss of ATM activator NKX3.1.">
		<entity id="s4.e1" charOffset="8-42"
			type="GO" text="cellular protein catabolic process" ontology_id="GO_0044257"/>
		<entity id="s4.e2" charOffset="71-94"
			type="GO" text="protein phosphorylation" ontology_id="GO_0006468"/>
		<entity id="s4.e3" charOffset="112-191"
			type="GO" text="positive regulation of transcription elongation from RNA polymerase II promoter" ontology_id="GO_0032968"/>
		<entity id="s4.e4" charOffset="190-196"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e4" pgr="false"/>
		<pair id="s4.p2" e1="s4.e3"
		    e2="s4.e4" pgr="false"/>
		<pair id="s4.p3" e1="s4.e2"
		    e2="s4.e4" pgr="true"/>
	</sentence>
	<sentence id="s5" text="regulation of cellular amino acid metabolic process genotypes of 390 negative regulation of phosphatase activity did not indicate predisposition to positive regulation of transcription elongation from RNA polymerase II promoter, yet loss of NQO1 in CaP suggested potential progression-opposing tumour suppressor role.">
		<entity id="s5.e1" charOffset="0-51"
			type="GO" text="regulation of cellular amino acid metabolic process" ontology_id="GO_0006521"/>
		<entity id="s5.e2" charOffset="61-140"
			type="GO" text="positive regulation of transcription elongation from RNA polymerase II promoter" ontology_id="GO_0032968"/>
		<entity id="s5.e3" charOffset="69-112"
			type="GO" text="negative regulation of phosphatase activity" ontology_id="GO_0010923"/>
		<entity id="s5.e4" charOffset="207-213"
			type="HP" text="tumour" ontology_id="HP_0002664"/>
		<pair id="s5.p1" e1="s5.e4"
		    e2="s5.e4" pgr="false"/>
		<pair id="s5.p2" e1="s5.e1"
		    e2="s5.e4" pgr="false"/>
		<pair id="s5.p3" e1="s5.e3"
		    e2="s5.e4" pgr="false"/>
	</sentence>
	<sentence id="s6" text="TMPRSS2-ERG rearrangenegative regulation of phosphatase activityt and negative regulation of protein phosphorylation loss, events sensitizing to PARPi, occurred frequently along with heterogeneous loss of DNA repair factors 53BP1, histone H3-K9 demethylation and negative regulation of transcription by RNA polymerase II (all studied here for the first time in positive regulation of transcription elongation from RNA polymerase II promoter) whose defects may cause resistance to PARPi.">
		<entity id="s6.e1" charOffset="21-64"
			type="GO" text="negative regulation of phosphatase activity" ontology_id="GO_0010923"/>
		<entity id="s6.e2" charOffset="70-116"
			type="GO" text="negative regulation of protein phosphorylation" ontology_id="GO_0001933"/>
		<entity id="s6.e3" charOffset="101-114"
			type="HP" text="heterogeneous" ontology_id="HP_0001425"/>
		<entity id="s6.e4" charOffset="205-284"
			type="GO" text="positive regulation of transcription elongation from RNA polymerase II promoter" ontology_id="GO_0032968"/>
		<entity id="s6.e5" charOffset="231-258"
			type="GO" text="histone H3-K9 demethylation" ontology_id="GO_0033169"/>
		<entity id="s6.e6" charOffset="263-320"
			type="GO" text="negative regulation of transcription by RNA polymerase II" ontology_id="GO_0000122"/>
		<pair id="s6.p1" e1="s6.e3"
		    e2="s6.e4" pgr="false"/>
		<pair id="s6.p2" e1="s6.e1"
		    e2="s6.e3" pgr="false"/>
		<pair id="s6.p3" e1="s6.e2"
		    e2="s6.e3" pgr="false"/>
		<pair id="s6.p4" e1="s6.e3"
		    e2="s6.e5" pgr="false"/>
		<pair id="s6.p5" e1="s6.e3"
		    e2="s6.e6" pgr="false"/>
	</sentence>
</document>
